Compared to 2007, it decreased from 2011 onward, increased with tumor size (except T4), and was more prevalent in node-positive patients and with higher grading, in patients receiving BCS followed by mastectomy compared to BCS alone and less prevalent in mastectomy alone, and in patients with another subtype than HR + /HER2−. This evidence concerns the gene HR and neoplasm.